Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 71

recruiting
3 987
countries
28
conditions
2 109

906 trials match your criteria

Hormone-refractory prostate cancer+1

Not recruiting

Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide

Autoimmune haemolytic anaemia+1

Not recruiting

Study for Patients with Advanced Malignancies: Continued Treatment with Parsaclisib Alone or with Itacitinib, Ruxolitinib, Ibrutinib, or Tafasitamab

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Burkitt's lymphoma+1

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed or Refractory Burkitt Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib

Hairy cell leukaemia

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Hairy Cell Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mesna

Richter's syndrome

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Richter Transformation (RT)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib

Waldenstrom's macroglobulinaemia+1

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Waldenstrom Macroglobulinemia Using a Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Systemic mastocytosis

Not recruiting

Study on the Safety and Effectiveness of CGT9486 for Patients with Nonadvanced Systemic Mastocytosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:3,4-Dimethyl-N-(2-Phenyl-1H-Pyrrolo[2,3-B]Pyridin-5-Yl)-1H-Pyrazole-5-Carboxamide

Study on the Effectiveness and Safety of Oral Azacitidine for Patients with Low or Intermediate-Risk Myelodysplastic Syndrome

Not recruiting
Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine

Pulmonary arterial hypertension

Not recruiting

Study on Selexipag and Bosentan for Children with Pulmonary Arterial Hypertension

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Bosentan

Anti-glomerular basement membrane disease

Not recruiting

Study on Imlifidase and Drug Combination for Treating Severe Goodpasture Disease in Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Partial seizures

Not recruiting

Study on the Effects of Azetukalner in Reducing Focal-Onset Seizures for Patients with Epilepsy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner

Heart failure with reduced ejection fraction

Not recruiting

Study on Vericiguat for Adults with Chronic Heart Failure with Reduced Ejection Fraction

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Vericiguat

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.